These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10768315)

  • 1. Effects of antiarrhythmic drugs on QT interval dispersion--relationship to antiarrhythmic action and proarrhythmia.
    Gillis AM
    Prog Cardiovasc Dis; 2000; 42(5):385-96. PubMed ID: 10768315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G
    Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced QT-interval prolongation: considerations for clinicians.
    Li EC; Esterly JS; Pohl S; Scott SD; McBride BF
    Pharmacotherapy; 2010 Jul; 30(7):684-701. PubMed ID: 20575633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of autonomic nervous activity in the antiarrhythmic effects of magnesium sulfate in a canine model of polymorphic ventricular tachyarrhythmia associated with prolonged QT interval.
    Chinushi M; Izumi D; Komura S; Ahara S; Satoh A; Furushima H; Washizuka T; Aizawa Y
    J Cardiovasc Pharmacol; 2006 Sep; 48(3):121-7. PubMed ID: 17031266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autonomic tone attenuates drug-induced QT prolongation.
    Smith AH; Norris KJ; Roden DM; Kannankeril PJ
    J Cardiovasc Electrophysiol; 2007 Sep; 18(9):960-4. PubMed ID: 17666066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracardiac QT variability in patients with structural heart disease on class III antiarrhythmic drugs.
    Tereshchenko LG; Fetics BJ; Berger RD
    J Electrocardiol; 2009; 42(6):505-10. PubMed ID: 19700170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of myocardial ischemia and type I antiarrhythmic drug therapy on exercise QT intervals.
    Gardner MJ; McCarthy DM; Josephson ME
    Can J Cardiol; 1985 Jan; 1(1):37-40. PubMed ID: 3850762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short QT syndrome: pharmacological treatment.
    Gaita F; Giustetto C; Bianchi F; Schimpf R; Haissaguerre M; Calò L; Brugada R; Antzelevitch C; Borggrefe M; Wolpert C
    J Am Coll Cardiol; 2004 Apr; 43(8):1494-9. PubMed ID: 15093889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of determination of QT dispersal intervals in anti-arrhythmia therapy].
    Konecná P; Dvorák R; Semrád B
    Vnitr Lek; 1999 Aug; 45(8):453-6. PubMed ID: 11045143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Mar; 146(10):451-60. PubMed ID: 15835343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of methadone on QT-interval dispersion.
    Krantz MJ; Lowery CM; Martell BA; Gourevitch MN; Arnsten JH
    Pharmacotherapy; 2005 Nov; 25(11):1523-9. PubMed ID: 16232014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization.
    Houltz B; Darpö B; Swedberg K; Blomström P; Crijns HJ; Jensen SM; Svernhage E; Edvardsson N
    Europace; 2000 Jan; 2(1):20-31. PubMed ID: 11225593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Failure of antiarrhythmia agents and understanding the phenomenon of proarrhythmia].
    Semrád B
    Vnitr Lek; 2003 Sep; 49(9):700-6. PubMed ID: 14584417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
    Wu L; Shryock JC; Song Y; Li Y; Antzelevitch C; Belardinelli L
    J Pharmacol Exp Ther; 2004 Aug; 310(2):599-605. PubMed ID: 15031300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).
    Hondeghem LM
    Novartis Found Symp; 2005; 266():235-44; discussion 244-50. PubMed ID: 16050272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.